Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Common variant of CETP gene correlated with atherosclerosis progression, response to pravastatin

Jan. 27, 1998

Wyeth-Ayerst licenses PEPCK-modulating compounds

Jan. 27, 1998

Squalene synthase inhibitors patented by Pfizer

Jan. 26, 1998

Alkermes, Johnson & Johnson to codevelop novel formulation of erythropoietin

Jan. 23, 1998

Efficacy and safety of oral contraception demonstrated in men

Jan. 23, 1998

Novel bone resorption inhibitors from ADIR

Jan. 23, 1998

Commencement of Ossigel clinical trials

Jan. 22, 1998

Yamasa presents novel xanthine oxidase inhibitors

Jan. 22, 1998

Antiprogestational agents with reduced antiglucocorticoid activity claimed by HHS

Jan. 21, 1998

Duphar presents new vitamin D analogues

Jan. 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...